TGTX vs. DYN, VERA, RCKT, ARVN, CORT, MRUS, RNA, AMPH, RYTM, and KROS
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Dyne Therapeutics (DYN), Vera Therapeutics (VERA), Rocket Pharmaceuticals (RCKT), Arvinas (ARVN), Corcept Therapeutics (CORT), Merus (MRUS), Avidity Biosciences (RNA), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
TG Therapeutics received 638 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. Likewise, 76.71% of users gave TG Therapeutics an outperform vote while only 64.71% of users gave Dyne Therapeutics an outperform vote.
TG Therapeutics presently has a consensus target price of $29.00, suggesting a potential upside of 104.08%. Dyne Therapeutics has a consensus target price of $37.43, suggesting a potential upside of 48.94%. Given TG Therapeutics' higher probable upside, equities research analysts plainly believe TG Therapeutics is more favorable than Dyne Therapeutics.
58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 9.2% of TG Therapeutics shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, TG Therapeutics had 9 more articles in the media than Dyne Therapeutics. MarketBeat recorded 11 mentions for TG Therapeutics and 2 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.55 beat TG Therapeutics' score of 0.10 indicating that Dyne Therapeutics is being referred to more favorably in the news media.
TG Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
TG Therapeutics has a net margin of 5.42% compared to Dyne Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 12.89% beat Dyne Therapeutics' return on equity.
Summary
TG Therapeutics beats Dyne Therapeutics on 12 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
